Neuraly Inc., a subsidiary of D&D Pharmatech Inc., and Enigma Biomedical USA, Inc. signed a research license and commercialization option agreement for PMI04, a PET imaging biomarker of neuroinflammation. The agreement grants Enigma an exclusive research license for PMI04 with the option to negotiate commercialization rights. PMI04 targets activated microglia, offering a potentially more specific approach than current TSPO-targeted PET imaging for diagnosing neurodegenerative diseases like Alzheimer’s, Parkinson’s, and multiple sclerosis.

This partnership is potentially groundbreaking for the neurodegenerative disease field. PMI04’s specificity to activated microglia could dramatically improve the accuracy and quantitative assessment of neuroinflammation. This could accelerate the development of effective therapies by providing researchers with a more reliable tool to measure treatment efficacy. Earlier and more accurate diagnoses could also significantly improve patient outcomes by enabling earlier intervention and potentially slowing disease progression.

Enigma will focus on developing PMI04 for neurodegenerative disease assessment. Neuraly will receive upfront and milestone payments tied to development and commercialization progress, as well as royalties on future sales, should the product reach the market. The agreement outlines a pathway for Enigma to obtain exclusive commercialization rights upon successful completion of the research phase.

This agreement signals a crucial step toward more precise diagnostic tools for neurodegenerative diseases. The potential of PMI04 to enhance the development and effectiveness of future treatments is significant. The success of this partnership could reshape the landscape of neurodegenerative disease diagnosis and ultimately improve the lives of patients affected by these debilitating conditions.

Source link: http://www.businesswire.com/news/home/20250116256666/en/Neuraly-and-Enigma-Biomedical-USA-announce-a-Research-License-and-Commercialization-Option-Agreement-for-PET-Imaging-Biomarker-PMI04

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.